A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andrew Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Cancer Center (data Collection Only)
Duarte, California, United States
- Memorial Sloan Kettering Basking Ridge (all Protocol Activities)
Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (all Protocol Activities)
Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (all Protocol Activities)
Montvale, New Jersey, United States
- Memorial Sloan Kettering Commack (all Protocol Activities)
Commack, New York, United States
- Memorial Sloan Kettering Westchester (all Protocol Activities)
Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (all Protocol Activities)
New York, New York, United States
- Memorial Sloan Kettering Rockville Centre (all Protocol Activities)
Rockville Centre, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 May 2021
- Primary completion
- 30 Jun 2027
- Completion
- 30 Jun 2027
- Last update posted
- 6 Jul 2026
- Registered enrollment
- 6
- Registry id
- NCT04416451
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.